Although clinical and experimental studies have long suggested a role for the renin-angiotensin system (RAS) in the regulation of erythropoiesis, the molecular basis of this role has not been well understood. We report here that transgenic mice carrying both the human renin and human angiotensinogen genes displayed persistent erythrocytosis as well as hypertension. To identify the receptor molecule responsible for this phenotype, we introduced both transgenes into the AT1a receptor null background and found that the hematocrit level in the compound mice was restored to the normal level. Angiotensin II has been shown to influence erythropoiesis by two means, up-regulation of erythropoietin levels and direct stimulation of erythroid progenitor cells. Thus, we conducted bone marrow transplantation experiments and clarified that AT1a receptors on bone marrow-derived cells were dispensable for RAS-dependent erythrocytosis. Plasma erythropoietin levels and kidney erythropoietin mRNA expression in the double transgenic mice were significantly increased compared with those of the wild-type control, while the elevated plasma erythropoietin levels were significantly attenuated in the compound mice. These results provide clear genetic evidence that activated RAS enhances erythropoiesis through the AT1a receptor of kidney cells and that this effect is mediated by the elevation of plasma erythropoietin levels in vivo.
subtypes, type 1 (AT1) and type 2 (AT2) receptors. In addition, rodents have two AT1 receptor isoforms, AT1a and AT1b, and a major role of the RAS in blood pressure regulation in these species is mediated mainly through the AT1a receptor (AT1aR), expression of which predominates over AT1bR in most organs (1, 2) .
Although a role for the RAS in the regulation of erythropoiesis has long been suspected, its mechanistic basis has not been fully defined (3) . Correlation between RAS activation and erythrocytosis has been suggested in a variety of clinical and pathological conditions (3) (4) (5) (6) (7) (8) . In both experimental animal and human studies, administration of renin or ANG II has been shown to increase erythropoietin (Epo) level, a potent humoral stimulator of erythropoiesis (9) (10) (11) (12) (13) (14) (15) (16) . In addition, several studies have demonstrated a direct role of ANG II in stimulating proliferation of erythroid progenitor cells via AT1 receptors in vitro (17, 18) . On the other hand, the inhibitory effect of ANG II on burst-forming units-erythroid (BFU-E) colony formation has also been reported (19) . Although a substantial number of clinical studies have established a link between the activation of the RAS and erythropoiesis, attempts to resolve the in vivo basis for this phenomenon are not fully realized, resulting in a degree of clinical confusion (3) .
Against this controversial background, three important questions on the interrelationship between the activated RAS and erythropoiesis remain unanswered: first, does chronic activation of the RAS physiologically modulate positive or negative erythropoiesis in vivo; second, which of the three angiotensin receptor subtypes, AT1a, AT1b, or AT2, mediates RAS-modulated erythropoiesis in vivo; and finally, do increased Epo levels, direct stimulation of erythroid progenitors, or both, play a principal role in RAS-modulated erythropoiesis?
In this study, we investigated these three questions using genetically engineered mice and bone marrow transplantation techniques.
MATERIALS AND METHODS

Animal model
Generation of mice containing both the human renin (hREN) and human angiotensinogen (hAGT) transgenes (Tsukuba hypertensive mice; THM) has been described previously (20) . In brief, hREN(+/+) and hAGT(+/+) transgenic mice (TgM) were cross-mated and the F1 progeny, hAGT(+/−)hREN(+/−), were termed THM (Fig. 1A, left) . A schematic of the breeding strategy used to generate THM in the AT1aR null background (THM/AT1-KO) is illustrated in Fig. 1A , right. The homozygous AT1aR-deficient [AT1aR(−/−), ref 1] mice and hREN(+/+) TgM were intercrossed to generate double heterozygous F1 progeny [hREN(+/−)/AT1aR(+/−)], which were then intercrossed to make hREN(+/+)/AT1aR(−/−) mice. hAGT(+/+)/AT1aR(−/−) mice were generated by a similar scheme. Finally, female hREN(+/+)/AT1aR(−/−) and male hAGT(+/+)/AT1aR(−/−) mice were interbred to produce hAGT(+/−)hREN(+/−)/AT1aR(−/−) compound mice. This genotype is hereafter referred to as THM/AT1-KO (Fig. 1A, right) . The genotype of the human AGT, human REN transgenes, and endogenous mouse AT1aR locus was determined by Southern blot analysis as described previously (1, 21, 22) with minor modifications. In brief, tail DNA was digested with appropriate restriction enzymes (REN; PstI, AGT; BglII and BamHI, AT1aR; EcoRI), electrophoresed on 0.7% agarose gels, transferred to nylon membranes, and hybridized with mouse REN (22) , mouse AGT (21) , and mouse AT1aR (1) probes, respectively. The mouse AGT and REN probes cross-hybridized with transgenic human fragments as well as endogenous mouse gene fragments. All mice were backcrossed into the C57BL/6J genetic background.
Measurement of hematocrit, reticulocyte counts, and plasma Epo levels
Three-month-old male mice were anesthetized with pentobarbital sodium, and 200 μl of blood were collected via the tail vein into a tube containing EDTA. Hematopoietic indices were determined using an automatic counter (Nihon Kohden, Tokyo, Japan). The number of reticulocytes was determined by staining peripheral blood with methylene blue of Capillot (Terumo, Tokyo, Japan), and reticulum-positive cells were counted per 1000 red blood cells per sample under microscopy. Plasma was also centrifuged for 10 min at 3,000 g and stored at −80°C until use, and Epo concentrations were analyzed with a commercial ELISA kit (Roche Diagnostics), according to the manufacturer's protocol as described previously (23) .
Bone marrow transplantation
Sixteen THM and eight wild-type (WT) C57BL/6J recipient mice aged 8−9 wk were lethally irradiated with 940 cGy (Hitachi, Deep X-ray Apparatus, Model MBR-1520R, Tokyo, Japan). Bone marrow cells were harvested from male donor WT C57BL/6J or AT1-KO mice aged 8 to 16 wk by flushing the ilia, femurs, and tibias with DMEM media containing 10% fetal bovine serum. Eight THM and eight WT recipient mice received 5 × 10 6 bone marrow cells in 1 ml PBS, which were devoid of erythrocytes, from male donor WT mice by tail vein injection 6 h after irradiation. The other eight recipients THM received marrow from donor AT1-KO mice. At age 14 wk, 100 μl of peripheral blood were collected from the tail vein and hematopoietic indices were determined as described above. Genomic DNA was extracted from the rest of the peripheral blood using lysis buffer (0.32 M sucrose, 10 mM Tris-HCl pH 7.5, 5 mM MgCl 2 , 1% Triton X-100), and the genotype was determined by PCR. Twenty-five cycles of PCR reaction with the hAGT gene-specific primer set (5′-CACGTCCTCAGCACTCAAAG-3′ and 5′-CAGGGATGTGCTAGTGTAAG-3′) amplified the human but not the mouse gene sequences. The PCR primer set for mouse GAPDH gene was as follows: 5′-GACCACAGTCCATGCCATCACT-3′ and 5′-TCCACCACCCTGTTGCTGTGA-3′. In preliminary transplantation experiments, we injected female marrows into male recipient mice and detected the genotype of the DNA from peripheral blood of recipient male mice by PCR using the Y chromosome-specific SRY gene, as well as the autosomal IL-3 gene primer sets (24) . The results confirmed that this procedure resulted in near-complete replacement of the peripheral blood (data not shown).
Total RNA isolation and real-time PCR
Total RNA was prepared from frozen kidneys according to the protocol of the RNA isolation system kit (Promega, Madison, WI). Reverse transcription was carried out at 42°C for 60 min in 20 μl of RT mixture containing 1 μg total RNA, 100 U reverse transcriptase (Toyobo, Osaka, Japan), 100 U RNase inhibitor (Invitrogen, Tokyo, Japan), 1 mM each dNTPs (TaKaRa, Kyoto, Japan), and 2.5 μM oligo d(T) 16 primer. The primer sequences were as follows: Epo 5′-GAGGCAGAAAATGTCACGATG-3′ and 5′-CTTCCACCTCCATTCTTTTCC-3′ (25); and GAPDH 5′-TCACTGGCATGGCCTTCC-3′ and 5′-CAGGCGGCACGTCAGATC-3′ The quantitative PCR reactions were carried out using SYBR Green PCR Master Mix reagents (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. PCR were cycled 40 times using the following conditions: 95°C for 15 s, 64°C for 1 min. The reaction for PCR contained 1 μl RT mixture, 200 nM forward primer, 200 nM reverse primer, and 25 μl SYBR Green PCR Master Mix reagents in a total volume of 50 μl. In each assay, PCRs were performed in duplicate for the standards and unknown samples to determine the relative quantities of Epo and GAPDH. The ABI Prism 7700 Sequence Detection System (Applied Biosystems) was used to run the PCR and collect fluorescence data. Results were analyzed using Sequence Detector v1.7 software (Applied Biosystems). To compare expression patterns in respective kidneys, mRNA template concentrations for Epo and GAPDH genes were calculated from the standard curve using sixfold dilutions of WT kidney cDNA. The mRNA quantity of each amplicon was calculated for each standard and experimental sample. After normalization for GAPDH, Epo genes were expressed relative to the WT kidney Epo expression. The average WT kidney Epo mRNA (n=6) was set at 100%.
Hep3B cell and kidney organ culture experiment
The Epo-producing hepatoma cell line Hep3B was obtained from the American Type Cell Collection (Rockville, MD). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies Inc., Gaitherburg, MD), supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT) in 175 cm 2 dishes. Cells were incubated in humidified 5% CO 2 /95% air at 37°C. Twentyfour hours before the start of the experiments, 8.0 × 10 5 cells were plated on 60-mm plates and incubated under conditions of hypoxia (1% oxygen) or normoxia (21% oxygen) for 12 h with ANG II (Peptide Institute, Osaka, Japan) at concentrations of 0, 0.1, 10 nM, or 1 μM. Supernatants from cell cultures were kept at −80°C until measurement. The EPO concentration of the supernatants was determined as described above. The experiments were performed in triplicate twice independently.
Measurement of blood pressure
Systolic, mean, and diastolic blood pressures were measured with a noninvasive computerized tail cuff blood pressure system in conscious mice (BP-98A; Softron) as described previously (20) .
Statistical analysis
Data are means ± SE. Statistical significance between groups was evaluated by the unpaired Student's t test. A P value of <0.05 was considered statistically significant.
RESULTS
Positive effects of RAS activation on erythropoiesis
Three-month-old male THM showed persistent erythrocytosis, with an ~25% increase in hematocrit levels (55.3±0.68%; n=20) compared with those of WT C57BL/6 male mice (44.1±0.51%; n=10; P<0.0001; Fig. 2A ). Hemoglobin levels were also elevated in THM (16.9 g/dl±0.27) as compared with WT mice (13.4 g/dl±0.19; P<0.0001). An increased hematocrit level was also observed in three-month-old female THM (56.48±1.089%; n=14) as compared with WT mice (43.6±1.51%; n=7; P<0.0001). In addition, persistent erythrocytosis was also observed in 6-month-old male THM (51.6±0.87%; n=9) compared with WT mice (40.0±0.49%; Male mice were used in the following analyses of erythrocytosis to avoid the potential influence of sex hormones like estrogen on Epo levels (26, 27) . Excessive erythrocytosis implies an increased number of reticulocytes. Indeed, reticulocyte count in peripheral blood at age 3 months was significantly increased in THM (37.0±2.9‰; n=8) compared with that in WT mice (21.3±0.92‰; n=9; P<0.001; Fig. 2B ). The increment in reticulocyte number suggested that erythrocytosis was associated with excessive production of erythrocytes. Further, splenomegaly, a secondary event to the erythrocytosis, was observed in THM (3.66±0.32 mg/g; n=20) as compared with WT mice (2.38±0.23 mg/g; n=10; P<0.05; Fig. 2C ). These data suggested that the erythrocytosis in THM was attributable to augmented erythrocyte production.
Major role of AT1a receptor in RAS-induced erythrocytosis
To genetically elucidate the receptor subtype responsible for the erythrocytosis, we generated TgM carrying both hREN and hAGT transgenes in the genetically disrupted background of one of the major ANG II receptors, AT1aR (THM/AT1-KO). Details are described in Materials and Methods (Fig. 1A) . The genotype of mice in each generation was determined by Southern blot analysis (Fig. 1B) . These THM/AT1-KO mice chronically overproduce ANG II in the absence of AT1aR, but survival rate and postnatal development were normal and they appeared healthy (data not shown).
Comparison of phenotypes between the THM and THM/AT1-KO mice allowed us to assess the contribution of AT1aR to RAS-induced erythrocytosis. As shown in Fig. 2A , the genetic deletion of AT1aR from the THM significantly restored hematocrit levels (THM/AT1-KO; 46.2±0.49%; n=10; P<0.0001 as compared with THM) to near-WT levels. Further, THM/AT1-KO mice showed a decreased reticulocyte number (THM/AT1-KO; 22.3±1.9‰; n=6; P<0.01 as compared with THM; (Fig. 2B) . Splenomegaly was also ameliorated compared with THM (THM/AT1-KO; 2.71±0.10 mg/g; n=10; P<0.05 as compared with THM; Fig. 2C ). These data thus suggested the reticulocytosis and splenomegaly as well as erythrocytosis induced by chronic activation of the RAS occurs mainly via AT1aR in vivo. The THM/AT1-KO mice showed a slight increase in hematocrit levels compared with WT mice (P<0.01), whereas reticulocyte number and spleen weight/body weight were not significantly different (P=0.54 and P=0.22, respectively).
Dispensable role of AT1a receptor on bone marrow cells for erythrocytosis
The genetic deletion of AT1aR in THM clearly demonstrated the involvement of this receptor subtype in erythrocytosis. It has been shown that the activated RAS influences erythropoiesis via two pathways: ANG II increases Epo production in vivo (9-16) and also directly stimulates or inhibits proliferation of normal early erythroid progenitors through AT1 receptors in vitro (17) (18) (19) . To examine whether the erythrocytosis observed in THM was due to increased production of Epo from kidney or liver cells or to the direct stimulation of early erythroid progenitors of bone marrow-derived cells, we conducted bone marrow transplantation experiments. If the erythrocytosis observed in THM results from the accelerated proliferation of erythroid progenitor cells mediated through AT1aR on bone marrow cells, then hematocrit levels in THM transplanted with the marrows of AT1-KO mice (THM←AT1-KO) should be decreased compared with those in THM transplanted with the marrows of WT mice (THM←WT), in accordance with the contribution of AT1aR on bone marrow cells to erythrocytosis. To verify the reconstitution of the bone marrow after transplantation, genomic DNA was extracted from peripheral blood at 5 wk posttransplantation, a sufficient period to ensure hematopoietic recovery after irradiation (28, 29) . Genotype exchange was determined by hAGT-specific PCR analysis (Fig. 3A) . Because the hAGT primer set amplified the AGT sequences in human but not in mouse genomic DNAs, this assay sensitively detected the residual amount of hAGT gene in the peripheral blood. The results indicated that peripheral blood was successfully exchanged by donor marrows. In addition, peripheral blood reconstitution in the mice of THM←AT1-KO groups was confirmed with a primer set specific for AT1a null allele (data not shown; ref 30) .
Hematocrit levels in the peripheral blood of each group of mice at 5 wk after bone marrow transplantation are shown in Fig. 3B . In both THM←WT and THM←AT1-KO groups, apparent erythrocytosis was observed compared with WT mice transplanted with the marrows of WT mice (WT←WT) (THM←WT; 52.6±0.95%, THM←AT1-KO; 52.5±0.86%, and WT←WT; 45.6±0.61%; n=8 in all groups) (THM←WT and THM←AT1-KO vs. WT←WT, P<0.01). Importantly, no significant difference (P=0.96) was observed in hematocrit levels between the THM<-WT and THM←AT1-KO groups. This result conclusively shows that AT1aR on bone marrow-derived cells is dispensable to the peripheral blood erythrocytosis induced by ANG II.
Plasma Epo levels and quantification of kidney Epo mRNA
These bone marrow transplantation results implied that the erythrocytosis induced by ANG II is mainly due to the stimulation of AT1aR present in the recipient organs, such as on kidney or liver cells. Given previous findings that ANG II stimulated Epo production in vivo (9-16), we next examined plasma Epo levels in each group of mice. As shown in Fig. 3C , THM showed significant elevation of plasma Epo level (THM; 93.28±6.47 mIU/ml; n=9) compared with WT mice (44.74±6.38 mIU/ml; n=9; P<0.0001). In contrast, THM/AT1-KO mice showed a reduced Epo level (THM/AT1-KO; 65.98±7.17 mIU/ml; n=10) compared with THM (P<0.05), although it was still significantly higher than that of WT mice (P<0.05).
To investigate whether elevated plasma Epo levels are the result of the increased Epo gene expression in the kidneys, the main source of Epo production in the adult stage, we examined kidney Epo mRNA in each group by quantitative real-time PCR. As shown in Fig. 3D , levels of Epo mRNA in THM kidney were ~4.7-fold higher than those in WT mice kidney (THM; 470.4±118.7%, n=6; P<0.05). In THM/AT1-KO mice, a decrease in Epo mRNA was observed (THM/AT1-KO; 196.2±61.8%, n=6) compared with THM, but this did not reach statistical significance (P=0.067).
This incomplete restoration of hematocrit and Epo levels in the absence of AT1aR suggested the involvement of other receptor subtypes in this process, such as AT1b. Taken together, our results demonstrated that the primary cause of the erythrocytosis observed in THM was the ANG IImediated overproduction of Epo, mainly through the stimulation of AT1aR on kidney cells.
Lack of significant effect of ANG II on Epo expression in Hep3B cells
Our results suggested that RAS activation induces overproduction of Epo via AT1 receptor in
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vivo. However, the in vitro molecular mechanistic basis of how ANG II overproduces Epo expression remains completely unknown. To identify the molecular pathway underlying ANG IIinduced Epo production, we next examined if ANG II could increase Epo production via AT1 receptors in cultured cells by testing if ANG II potentiated Epo production in Hep3B hepatoma cells, considered a good model for the analysis of Epo gene regulation (31) . Hep3B cells were cultured under normoxic and hypoxic conditions in the presence of ANG II (0, 0.1, 10 nM, or 1 μM), and Epo concentrations in culture supernatants were determined by ELISA. As shown in Fig. 4 , although Epo expression was significantly elevated under hypoxic conditions, ANG II incubation did not change Epo expression in either normoxia or hypoxia.
Role of AT1aR in blood pressure regulation in THM
Because the role of AT1aR in blood pressure changes in the chronic activated states of the RAS has not been established, we measured blood pressure of each group of mice. Systolic blood pressure in THM/AT1-KO mice was significantly lower (98.2±1.64 mmHg) than that in THM (134.4±2.65 mmHg; P<0.0001) and even lower than that in WT mice (106.3±1.52 mmHg; P<0.01) but was significantly higher than that of AT1-KO mice (79.2±2.50 mmHg; P<0.0001). Average systolic blood pressure in each group is shown in Fig. 5 . These results demonstrated an important but incomplete depressor role of AT1aR deficiency in blood pressure regulation under chronic activation of the RAS.
DISCUSSION
An interrelationship between the activation of the RAS and erythrocytosis was first suggested by observations of patients in activated RAS conditions, such as renal artery stenosis (4), reninsecreting tumors (6, 7) , and postrenal transplant erythrocytosis (8) and in those undergoing chronic hemodialysis (32) . Previous experiments provided two plausible mechanisms for RASmodulated erythropoiesis, namely the increased production of Epo (9-16) and the direct stimulation of erythroid progenitor cells via AT 1 receptors (17) (18) (19) . Although a number of reports have suggested an interrelationship between the RAS and positive erythropoiesis, to our knowledge no clear in vivo experimental evidence for this issue had been presented, owing to a lack of appropriate genetically engineered models. In this respect, THM is an ideal mouse model that demonstrates chronic activation of the RAS, elevated plasma levels of ANG II, and persistent hypertension (20) . Use of this mouse allowed us to demonstrate in the present study that chronic activation of the RAS has positive effects on erythropoiesis in vivo.
To genetically elucidate the relationship between RAS-induced erythrocytosis and AT1aR, we generated hREN and hAGT double TgM in an AT1aR null genetic background (Fig. 1) . Such genetic manipulation confers at least three advantages over administration of AT1 receptor antagonists or ACE inhibitors to THM. First, chronic and high-dose administration of ACE inhibitors or AT1-receptor antagonists is inevitably accompanied by drug toxicity, including hematopoietic toxicity (33, 34) . Second, whereas humans have a single AT1 receptor, rodents possess two AT1 receptor isoforms, designated AT1aR and AT1bR. These receptors are highly homologous and their respective in vivo functions are difficult to distinguish using pharmacological approaches. By genetically deleting AT1aR from THM, in contrast, we were able to verify the in vivo significance of AT1aR in blood pressure maintenance as well as erythropoiesis under conditions of a chronically activated RAS (Figs. 2 and 5) . Third, accumulating evidence suggests that ANG II-derived angiotensin fragments, such as angiotensin III, IV, or angiotensin (1-7), are biologically active and integral components of the RAS, and novel receptors for these fragments have been reported (35, 36) . Although it is conceivable that angiotensin fragment levels are augmented in THM in proportion to the increase in ANG II production and act via their predicted receptors, our genetic evidence proved that the receptor responsible for peripheral blood erythrocytosis in vivo is the AT1aR (Fig. 2) .
Several groups have suggested the importance of a direct stimulatory effect of ANG II on the proliferation of erythroid progenitor cells in vitro (17, 18) . To the contrary, another group has reported an inhibitory effect of ANG II on BFU-E (19) . One of the former groups has also shown that AT 1 receptors are present on BFU-E and that the proliferative effect of ANG II on BFU-E is blocked by AT 1 receptor antagonists. Moreover, in several clinical conditions such as postrenal transplant erythrocytosis, many groups have demonstrated the up-regulation of AT 1 receptors in erythroid progenitor cells (8) . Considering these findings, it is greatly surprising that our bone marrow transplantation experiments clearly showed only a minor effect of the lack of AT1aR in bone marrow-derived cells on peripheral blood erythrocytosis under chronic activation of the RAS in vivo (Fig. 3B) . Although the role of AT1aR on bone marrow-derived cells under pathophysiological and clinical conditions remains to be elucidated, our results demonstrate that the primary cause of erythrocytosis induced by chronic RAS activation is mediated by AT1aR on the recipient organ cells and that stimulation of the pathway has a far more important physiological effect on erythropoiesis.
Epo, a glycoprotein produced mainly in renal cells in the adult stage, strongly regulates red cell production (37, 38) . It is well established that, under physiological conditions, plasma Epo protein level shows an inverse relationship with hematocrit level. One might expect that, if erythrocytosis were caused by a mechanism independent of Epo, plasma Epo levels would be routinely kept low by negative feedback regulation. Our finding that THM with erythrocytosis exhibited elevated levels of plasma Epo and increased Epo mRNA in kidney indicates that ANG II stimulated Epo production in THM and suggests that the primary cause of the erythrocytosis observed in THM was the elevated plasma Epo levels from kidney cells (Fig. 3C and D ).
An in vivo effect of acute infusion of renin or ANG II on augmented plasma Epo production has been suggested in animal models since the 1960s (9, 10) . We attempted to clarify the transcriptional molecular mechanism of ANG II-induced Epo production using Hep3B cells and showed that while ANG II augmented plasma Epo levels and mRNA Epo transcription in vivo, further analysis indicated that endogenous Epo production was not augmented by ANG II in hepatoma cell lines in vitro. Similar results were more recently described using HepG2 hepatoma cells (39) , further suggesting that endogenous Epo production is not augmented by ANG II in hepatoma cell lines. It remains unclear how ANG II increases plasma Epo levels. The mechanism of ANG II-induced Epo production is a subject for future study, since cell lines from the kidney, the most prominent Epo production site, are still not available for Epo gene regulation.
From our study, we speculated on the mechanism of the correlation between blood pressure regulation and erythropoiesis induced by RAS activation. If hematocrit levels were regulated by blood pressure itself, THM/AT1-KO (mean blood pressure 98.2 mmHg) should have had lower hematocrit levels than WT mice (mean blood pressure 106.3 mmHg). However, our data showed that THM/AT1-KO had slightly but significantly higher hematocrit levels (average Hct 46.2%) than WT mice (average Hct 44.1%). From these results, we speculate that both RAS-induced blood pressure and erythropoiesis are positively mediated but are differently regulated by AT1aR.
In conclusion, our novel findings indicate that 1) the systemic and persistent activation of RAS enhances erythropoiesis in vivo, 2) the major receptor subtype responsible for erythropoiesis in vivo is the AT1aR, 3) the lack of AT1aR in bone marrow-derived cells has a negligible effect on peripheral blood erythrocytosis, and 4) increased Epo levels via stimulation of AT1aR on kidney cells play a major role in erythrocytosis. In clinical situations, although it is generally accepted that RAS activation enhances erythropoiesis, whether ARBs reduce erythropoiesis remains controversial and differs among clinical settings. Our results suggest that the blockade of AT1 receptors has the potential to decrease erythrocytosis to at least normal levels in RAS-activated conditions. This may explain the contradictory results seen to date in human studies. Our results provide insights into the physiological relationship and clinical situation that exists between the RAS and erythropoiesis. Hematocrit levels of mice at 5 wk after bone marrow transplantation. Mean hematocrit levels are ± SE. THM←WT, for example, represents THM transplanted with bone marrow of WT mice; n = 8 for all groups. *P < 0.01 vs. WT←WT. N.S., not significant. C) Plasma Epo level was measured in WT, THM, and THM/AT1-KO mice at age 3 months, and the results are expressed as relative to that in WT mice (set at 100%). Number of mice in each group was as follows: WT, 9; THM, 9; and THM/AT1-KO, 10. *P < 0.05, **P < 0.0001 vs. WT. + P < 0.05 vs. THM. D) Total RNA was isolated, and erythropoietin expression was determined by quantitative real time PCR. Data are indicated as the relative expression to that of average WT mice kidney Epo mRNA normalized for GAPDH (set at 100%); n = 6 for all groups. *P < 0.05 vs. WT. 5 . Blood pressure in mice. Systolic blood pressure of WT, THM, THM/AT1-KO, and AT1-KO mice was measured by automated tail cuff method in conscious condition as described previously (20) . Mean systolic blood pressure of each group is ± SE. Number of animals examined ranged from 10 to 13 for each genotype. *P < 0.01 vs. WT. **P < 0.0001 vs. THM. 
